Interesting Endo: Fracture Risk & Endocrine Disruptors
Our April list includes predictors of fracture risk, endocrine-disrupting chemicals, and CV effects of thyroid dysfunction.
Adjuvant Metformin in Type 1 Diabetes
This study is the first retrospective, long-term analysis of metformin as adjuvant therapy to insulin in patients with T1DM.
Renal Effects: SGLT2 Inhibitors in Type 2 Diabetes
A meta-analysis compared the renal side effects of SGLT2 inhibitors in patients with type 2 diabetes.
Screen Time and Insulin Resistance in Children
The health effects of sedentary behavior, such as screen time, include adiposity & T2DM risk in adults. How does screen time affect children?
CV Events: Safety of Insulin
A study compared mortality and major adverse cardiovascular events in patients with type 2 diabetes prescribed metformin or insulin.
Interesting T2DM: Pharmacotherapy & Obesity Outcomes
Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.
GLP-1 Agonists: Beneficial in Low-Risk Patients?
Do low-risk CVD patients with T2DM experience the same significantly lower all-cause and CV mortality seen in high-risk patients?
Can Liraglutide Delay Diabetes Onset?
Researchers compared time to onset of diabetes in a group of patients with obesity and pre-diabetes treated with liraglutide or placebo.
Dapagliflozin: All-Cause & Cardiovascular Mortality
Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?
Endo News Roundup: Diabetes and Cardiovascular Disease
Studies include drug-free remission of T2DM, and the impact of hyperglycemia and hypoglycemia on cardiovascular health.
Interesting Endo: T Trials & T1DM Self Care
Our March list includes Testosterone Trials results, self-management in patients transitioning to adult care, and cancer mortality risk with diabetes.
By clicking Accept, you agree to become a member of the UBM Medica Community.